RecruitingPhase 1Phase 2NCT07815678

First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671

A Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food-effect of ACCG-2671

Sponsor

Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics

Enrollment

164 participants

Start Date

Dec 29, 2025

Study Type

INTERVENTIONAL

Conditions

Obesity

Summary

This first-in-human study will evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of ACCG-2671. It will also evaluate the effect of food on the pharmacokinetics, safety, and tolerability of a single dose. Parts 1 and 2 will enroll healthy participants, and Part 3 will enroll otherwise healthy participants with obesity.

Eligibility

Min Age: 25 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called ACCG-2671 and a drug called Placebo for people with obesity. The study is currently recruiting participants at 6 locations. People eligible for this study include aged 25 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.